Homocyst(e)ine, oxidative stress, and endothelium function in uremic patients.
Moderate hyperhomocyst(e)inemia and impaired endothelium-dependent vasodilatation are present in uremic patients. However, the precise mechanism(s) underlying the link between moderate hyperhomocyst(e)inemia and endothelium dysfunction in uremic patients remains to be determined. Experimental and clinical evidence have led to the suggestion that moderate hyperhomocyst(e)inemia may predispose to endothelium dysfunction through a mechanism that involves generation of reactive oxygen species and a decrease in nitric oxide bioavailability. Recent preliminary findings in uremic patients provide support for some aspects of this suggestion. These data must be confirmed in additional studies. Moreover, the relative importance of homocysteine-induced oxidant stress versus other potential mechanisms of endothelium dysfunction in these patients remains to be determined.
Massy
Z A
ZA
Division of Nephrology, INSERM U507, and Biochemistry A and B Laboratories, Necker Hospital, Paris, France. massy@necker.fr
Ceballos
I
I
Chadefaux-Vekemens
B
B
Nguyen-Khoa
T
T
Descamps-Latscha
B
B
Drüeke
T B
TB
Jungers
P
P
D000818:Animals; D001161:Arteriosclerosis / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control; D004730:Endothelium, Vascular / Q000503:physiopathology*; D006710:Homocysteine / Q000378:metabolism*; D006711:Homocystine / Q000378:metabolism*; D006801:Humans; D020138:Hyperhomocysteinemia / Q000209:etiology / Q000378:metabolism; D009569:Nitric Oxide / Q000378:metabolism; D018384:Oxidative Stress; D017382:Reactive Oxygen Species / Q000378:metabolism; D014511:Uremia / Q000150:complications / Q000378:metabolism* / Q000503:physiopathology*; D014664:Vasodilation / Q000502:physiology
D017382:Reactive Oxygen Species; D006710:Homocysteine; D009569:Nitric Oxide; D006711:Homocystine